There are no vaccines or antiviral treatments approved for Marburgvirus disease. No monoclonal antibodies against Marburgviruses are currently approved for clinical use by the FDA.
Our study describes the discovery and characterization of a diverse panel of antibodies against marburgvirus GP (glycoprotein) induced by multivalent immunization and provides candidate immunotherapeutics for further study and development.
Prophylactic or therapeutic countermeasures to marburgvirus infection outbreaks.
Potential for protective immunity to Marburgvirus.